Orrick Advises Bayer on Collaboration and Joint Venture with Arvinas


Orrick has advised Bayer on its collaboration with biopharmaceutical company Arvinas (Nasdaq: ARVN) to leverage Arvinas’ PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological and gynecological diseases. In addition, Bayer and Arvinas will jointly launch a new company to leverage Arvinas’ PROTAC® technology for agricultural applications. The overall series of arrangements includes over $110 million in upfront cash and committed funding for the human disease collaboration, the agricultural joint venture and a direct equity investment by Bayer in Arvinas.

The transaction is subject to customary closing conditions

The Orrick team was led by Matthew Gemello and included Ramy Shweiky, Thomas Joraanstad, Stephen Chao, Diana Gillis, Patrick Herman, Alex Okuliar and Eric Wall.